Evidence map›Paper›PMID 42761917›Full record

ReviewMethodist DeBakey cardiovascular journal2026

Familial Hypercholesterolemia.

Iulia Iatan, Jacques Genest

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Methodist DeBakey cardiovascular journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Iulia IatanResearch Institute of the McGill University Health Centre, Department of Medicine, McGill University, Montreal, Quebec, Canada.ORCID https://orcid.org/0000-0002-7266-2762
Jacques GenestFaculty of Medicine, Research Institute of the McGill University Health Centre, Montreal, McGill University, Quebec, Canada.ORCID https://orcid.org/0000-0003-2248-9663

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Familial hypercholesterolemia (FH) is a semi-dominant, autosomal, monogenic lipoprotein disorder characterized by severe elevations in low-density lipoprotein cholesterol (LDL-C) and premature atherosclerotic cardiovascular disease (ASCVD). The most common form, heterozygous FH, has an estimated prevalence of approximately 1 per 311 individuals, making it one of the most common hereditary disorders in medicine. FH is caused by pathogenic variants in the LDL receptor (

Indexed as

Anticholesteremic AgentsCholesterol, LDLHyperlipoproteinemia Type IIBiomarkersBlood Component RemovalFemaleGenetic Predisposition to DiseaseHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMutationPCSK9 InhibitorsPhenotypePrevalenceProprotein Convertase 9Receptors, LDLAnticholesteremic AgentsBiomarkersCholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsLDLR protein, humanPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9Receptors, LDLSerine Proteinase Inhibitorsatherosclerotic cardiovascular disease (ASCVD)cholesterolfamilial hypercholesterolemia (FH)lipid-lowering therapieslow-density lipoprotein (LDL)

Identifiers

PMID42761917
PMCPMC13588205

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.